JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017--
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE:
TEVA) announced today that it has filed its 2016 Annual Report on Form
20-F with the U.S. Securities and Exchange Commission. The Annual Report
can be found on the company’s website at www.tevapharm.com
as well as on the SEC website at www.sec.gov.
In addition, security holders may request a hard copy of the Annual
Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva
Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by
phone at (215) 591-8912.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by approximately 200 million
patients in 100 markets every day. Headquartered in Israel, Teva is the
world’s largest generic medicines producer, leveraging its portfolio of
more than 1,800 molecules to produce a wide range of generic products in
nearly every therapeutic area. In specialty medicines, Teva has the
world-leading innovative treatment for multiple sclerosis as well as
late-stage development programs for other disorders of the central
nervous system, including movement disorders, migraine, pain and
neurodegenerative conditions, as well as a broad portfolio of
respiratory products. Teva is leveraging its generics and specialty
capabilities in order to seek new ways of addressing unmet patient needs
by combining drug development with devices, services and technologies.
Teva's net revenues in 2016 were $21.9 billion. For more information,
View source version on businesswire.com: http://www.businesswire.com/news/home/20170215006382/en/
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
C. Mannix, 215-591-8912
Ran Meir, 215-591-3033
Amitai, 972 (3) 926-7656
Codner, 972 (3) 926-7687